PMID- 36072615
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231228
IS  - 2090-2840 (Print)
IS  - 2090-2859 (Electronic)
IS  - 2090-2840 (Linking)
VI  - 2022
DP  - 2022
TI  - Clinical Value of Pleural Effusion and Serum MMP-3 and CYFRA21-1 Combined with 
      ADA in Differential Diagnosis of Pleural Exudative Effusion.
PG  - 1615058
LID - 10.1155/2022/1615058 [doi]
LID - 1615058
AB  - OBJECTIVE: The aim of the study is to investigate the clinical value of matrix 
      metalloproteinases-3 (MMP-3) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) 
      combined with adenosine deaminase (ADA) in pleural effusion and serum in benign 
      and malignant pleural exudative effusion (PEE). METHODS: A total of 119 adult 
      patients with PEE admitted in our hospital from May 2018 to October 2021 were 
      selected. According to the patient's condition, the patients were divided into 
      the benign group (n = 75) and the malignant group (n = 44). The levels of MMP-3, 
      CYFRA21-1, and ADA in pleural effusion and serum were detected. The receiver 
      operating characteristic (ROC) curve was used to analyze the individual and 
      combined predictive value of MMP-3, CYFRA21-1, and ADA levels. RESULTS: In the 
      malignant group, the pleural effusion and serum MMP-3 and CYFRA21-1 levels were 
      higher than those in the benign group and the ADA levels were lower than those in 
      the benign group (P < 0.05). In the malignant group, the positive detection rate 
      of pleural effusion and serum MMP-3 and CYFRA21-1 was higher than that in the 
      benign group and the positive detection rate of pleural effusion and serum ADA 
      were lower than that in the benign group (P < 0.05). The AUC of pleural effusion 
      MMP-3, serum MMP-3 and the combination of them in the diagnosis of PEE were 
      0.764, 0.722 and 0.810, respectively. The AUC of pleural effusion CYFRA21-1 and 
      serum CYFRA21-1 and combination of them in the diagnosis of PEE were 0.776, 0.748 
      and 0.822, respectively. The AUC of pleural effusion ADA, serum ADA and their 
      combination in differential diagnosis of PEE were 0.762, 0.737 and 0.836, 
      respectively. The AUC of pleural effusion and serum of MMP-3 and CYFRA21-1 
      combined with ADA for differential diagnosis of PEE was 0.923. CONCLUSIONS: The 
      diagnostic efficacy of MMP-3 combined with CYFRA21-1 and ADA in pleural effusion 
      and serum for benign and malignant PEE are better than single index, which has 
      certain clinical values for the selection of early intervention scheme for PEE 
      patients.
CI  - Copyright (c) 2022 Zhiyang Xu et al.
FAU - Xu, Zhiyang
AU  - Xu Z
AD  - Department of Thoracic Surgery, The Third Clinical Medical College of Fujian 
      Medical University, The First Hospital of Putian, Putian 351100, Fujian, China.
FAU - Guan, Jun
AU  - Guan J
AD  - Department of Thoracic Surgery, The Third Clinical Medical College of Fujian 
      Medical University, The First Hospital of Putian, Putian 351100, Fujian, China.
FAU - Xu, Jianxin
AU  - Xu J
AUID- ORCID: 0000-0002-9916-8991
AD  - Department of Thoracic Surgery, The Third Clinical Medical College of Fujian 
      Medical University, The First Hospital of Putian, Putian 351100, Fujian, China.
FAU - Tu, Jiahua
AU  - Tu J
AD  - Department of Thoracic Surgery, The Third Clinical Medical College of Fujian 
      Medical University, The First Hospital of Putian, Putian 351100, Fujian, China.
FAU - Cheng, Jiangdong
AU  - Cheng J
AD  - Department of Thoracic Surgery, The Third Clinical Medical College of Fujian 
      Medical University, The First Hospital of Putian, Putian 351100, Fujian, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220829
PL  - Egypt
TA  - Emerg Med Int
JT  - Emergency medicine international
JID - 101567070
RIN - Emerg Med Int. 2023 Dec 20;2023:9765351. PMID: 38152429
PMC - PMC9444443
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/09/09 06:00
MHDA- 2022/09/09 06:01
PMCR- 2022/08/29
CRDT- 2022/09/08 02:29
PHST- 2022/07/04 00:00 [received]
PHST- 2022/08/04 00:00 [accepted]
PHST- 2022/09/08 02:29 [entrez]
PHST- 2022/09/09 06:00 [pubmed]
PHST- 2022/09/09 06:01 [medline]
PHST- 2022/08/29 00:00 [pmc-release]
AID - 10.1155/2022/1615058 [doi]
PST - epublish
SO  - Emerg Med Int. 2022 Aug 29;2022:1615058. doi: 10.1155/2022/1615058. eCollection 
      2022.